查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球自动注射器市场 - 2023-2030 年
市场调查报告书
商品编码
1319138

全球自动注射器市场 - 2023-2030 年

Global Autoinjectors Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

全球自动注射器市场规模在 2022 年达到 87 亿美元，预计到 2030 年将达到 297 亿美元，2023-2030 年的复合年增长率为 17.2%。推动全球自动注射器市场增长的因素包括：技术进步、人口老龄化加剧、癌症和糖尿病等慢性病发病率上升、患者医疗保健支出增加以及研发活动日益增多。

自动注射器是一类重要的医疗器械，可通过皮下或肌肉注射途径给药。它们可以方便地自行给药，而且剂量准确。它可以立即治疗过敏性休克、偏头痛等急症和糖尿病、多发性硬化症、类风湿性关节炎等其他慢性疾病。

市场动态

多发性硬化症发病率的增加促进了市场增长

多发性硬化症发病率的增加在促进市场增长方面发挥了重要作用。多发性硬化症（MS）是一种潜在的大脑和脊髓（中枢神经系统）致残性疾病。多发性硬化症患者的免疫系统会攻击覆盖神经纤维的保护鞘（髓鞘），从而导致大脑与身体其他部位之间的通信问题。

多发性硬化症患者人数的增加将增加自动注射器的使用量。例如，据多发性硬化症探索论坛称，全球约有 250 万人患有多发性硬化症。据估计，美国每周新增 200 例诊断病例。因此，多发性硬化症病例的增加推动了市场的增长。

老年人口的增加放大了市场增长

老年人口发病率的增加正在扩大市场的增长。年龄因素将影响市场。由于老年人的增加，他们无法长期住院治疗。老年人更容易患哮喘、糖尿病等疾病。

为了规避风险，老年人群会选择便捷的方法。因此，老年人口的增加将推动市场的发展。例如，根据美国国立卫生研究院（NIH）的报告，老年患者与哮喘相关的死亡率最高，每百万人中有 51.3 人。因此，老年人口的增加将扩大市场增长。

与设备相关的并发症将抑制市场增长

与使用设备相关的并发症会降低市场增长。使用自动注射器会产生许多副作用和并发症。例如，根据欧洲心脏病学会的研究，与自动注射器相关的副作用包括心跳加快/加速、紧张、出汗、恶心、呕吐、呼吸困难、头痛、头晕、焦虑、颤抖或皮肤苍白。因此，该设备并发症的增加会对市场产生负面影响。

COVID-19 影响分析

COVID-19 的流行加快了自我注射的趋势，使患者能够更积极地控制治疗。这一方向促进了自动注射器市场的更新技术，以加强注射速度调节、注射部位疼痛和治疗焦虑。

此外，在 COVID-19 大流行期间，主要企业推出的新产品也推动了市场的发展。例如，2020 年 4 月，梯瓦制药美国公司宣布，AJOVY（fremanezumab-vfrm）注射剂的自动注射器装置已在美国上市。AJOVY适用于成人偏头痛的预防性治疗，是唯一可选择每季度（675 毫克）和每月（225 毫克）皮下注射给药的抗降钙素基因相关肽（CGRP）预防性偏头痛治疗药物。

此外，诺华公司于 2021 年 9 月报告了一项国际 IIIb 期研究的数据，该研究显示，用 2 毫升自动注射器（UnoReady 笔）注射 300 毫克 Cosentyx（secukinumab）治疗轻度至重度斑块状银屑病成人患者，疗效显著，用药正确1。这些数据已在欧洲皮肤病与性病学会 30 周年大会上公布。

此外，尽管大流行病带来了严峻的现实，但更广泛的给药市场历来表现出持续、健康的增长。随着全球开始从 COVID-19 的长期影响中恢复过来，并接近一个更加稳定和正常的时期，市场有望蓬勃发展。

俄乌战争影响分析

据估计，俄乌冲突对自动注射器市场的影响不大，因为该地区的主要市场参与者较少。不过，在预测期内，原材料进出口的影响预计对自动注射器市场的增长影响不大。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第 3 章：执行摘要

  • 按类型分類的片段
  • 按应用划分
  • 按最终用户划分
  • 按地区划分

第四章：动态

  • 影响因素
    • 驱动因素
      • 过敏症患者人数增加
      • 慢性疾病数量增加
    • 限制因素
      • 与设备相关的并发症
    • 机会
      • 临床试验和新设备上市数量增加
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情况
    • COVID-19 期间的情景
    • COVID-19 后的情况
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第 7 章：按类型划分

  • 一次性自动注射器
  • 可重复使用的自动注射器

第八章：按应用分类

  • 类风湿关节炎
  • 银屑病关节炎
  • II 型糖尿病
  • 其他

第九章：按最终用户分类

  • 家庭护理
  • 医院
  • 其他

第 10 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第 11 章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併与收购分析

第十二章 ：公司简介

  • AbbVie
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • Amgen
  • Biogen Idec
  • AstraZeneca
  • Mylan
  • Pfizer
  • Teva Pharmaceuticals
  • Merck & Co
  • Johnson &Johnson
  • Becton Dickinson and Company

第 13 章 ：附录

简介目录
Product Code: MD1117

Market Overview

Global Autoinjectors Market reached US$ 8.7 billion in 2022 and is expected to reach US$ 29.7 billion by 2030 growing with a CAGR of 17.2% during the forecast period 2023-2030. The global autoinjectors market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of chronic diseases such as cancer and diabetes, rising patient healthcare expenditure and growing research and development activities.

These are important classes of medical devices that can deliver drugs through the subcutaneous or intramuscular route. They can be easily self-administered, and accurate doses can be given. It is an immediate treatment for emergency conditions such as anaphylaxis, migraine, and other chronic diseases such as diabetes, multiple sclerosis, rheumatoid arthritis, and others.

Market Dynamics

An increase in the Incidence of Multiple Sclerosis is Boosting the Market Growth

An increase in the incidence of multiple sclerosis cases is playing a major role in boosting market growth. Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.

An increase in the number of MS patients will increase the usage of autoinjectors. For instance, according to the MS Discovery Forum, an estimated 2.5 million people live with multiple sclerosis worldwide. An estimated 200 new cases are diagnosed each week in the United States. Thus, an increase in the number of MS cases is driving the market growth.

An Increase in the Geriatric Population is Magnifying the Market Growth

The increase in the incidence of the geriatric population is expanding the growth of the market. The age factor will influence the market. As there is an increase in aged people, they cannot go for hospitalization for a long period. Aged people are more prone to diseases such as asthma, diabetes, and many others.

In order to avoid the risks, aged groups will prefer convenient methods. Thus, an increase in the number of aged population will drive the market. For instance, according to NIH, elderly patients have the highest reported asthma-related mortality at 51.3 per million persons. Thus increase in the number of older population will expand the market growth.

Complications Associated with the Devices will Decline the Market Growth

The complications associated with the use of the devices can decline the growth of the market. There are a number of side effects and complications associated with the use of auto-injectors. For instance, according to the European Society of Cardiology, the side effects associated with auto-injector are fast/pounding heartbeat, nervousness, sweating, nausea, vomiting, trouble breathing, headache, dizziness, anxiety, shakiness, or pale skin may occur. Thus, an increase in the complications of the devices can affect the market negatively.

COVID-19 Impact Analysis

The COVID-19 epidemic has quickened the trend of self-injection, allowing patients to become more active and in control of their treatment. The direction has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.

In addition, the new products launched by key players are driving the market during the COVID-19 pandemic. For instance, in April 2020, Teva Pharmaceuticals USA, Inc. announced that the autoinjector device for AJOVY (fremanezumab-vfrm) injection is available in the United States. AJOVY is implied for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

Also, in September 2021, Novartis reported data from an international Phase IIIb study, which delivered treatment with Cosentyx (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high effectiveness and proper administration in adults with mild to severe plaque psoriasis1. These data were presented at the European Academy of Dermatology and Venereology's 30th Anniversary Congress.

Moreover, the broader drug delivery market has historically shown consistent, healthy growth, despite the grim realities of the pandemic. As the world begins to recover from the long-lasting effects of COVID-19 and approaches a period of greater stability and normality, markets are expected to flourish.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the Autoinjectors Market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Autoinjectors Market growth over the forecast period.

Segment Analysis

The autoinjectors market is segmented based on type, application, and end user.

The Type-2 Diabetes Mellitus Segment Accounts for Approximately 34.7% of the Autoinjectors Market Share

Due to the rise in the number of type-2 diabetic patients diseases, the segment holds the highest market share. For instance, according to Healthline, about 1.4 million new cases of diabetes are diagnosed in the United States every year. More than one in every ten adults who are 20 years or older has diabetes. For seniors (65 years and older), that figure rises to more than one in four.

Geographical Analysis

Europe accounted for Approximately 28.4% of the Market Share Owing to Technological Advancements

The rise in collaborations, clinical trials, and innovation of new devices is holding this region in this position. A number of clinical trials and approvals have been taking place in this region in order to make patients available for a number of treatments.

For instance, Aptar Pharma teams up with BD to develop a novel auto-injector. Aptar Pharma has signed an exclusive development and license agreement with BD Becton, Dickinson, and Company (BD). Thus, the increase in company collaborations, technological advancements, and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the autoinjectors market include: AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Merck & Co, Johnson & Johnson, and Becton Dickinson and Company among others.

Why Purchase the Report?

  • To visualize the auto-injector segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Autoinjectors Market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The Autoinjectors Market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet By Type
  • 3.2. Snippet By Application
  • 3.3. Snippet By End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased number of people with allergies
      • 4.1.1.2. Increase in the number of chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the devices
    • 4.1.3. Opportunity
      • 4.1.3.1. Increased number of clinical trials and new launches of devices
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Disposable Autoinjectors
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Reusable Autoinjectors

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Rheumatoid Arthritis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Psoriatic Arthritis
  • 8.4. Type II Diabetes Mellitus
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Home care setting
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AbbVie
    • 12.1.1. Company Overview
    • 12.1.2. ProductPortfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Amgen
  • 12.3. Biogen Idec
  • 12.4. AstraZeneca
  • 12.5. Mylan
  • 12.6. Pfizer
  • 12.7. Teva Pharmaceuticals
  • 12.8. Merck & Co
  • 12.9. Johnson &Johnson
  • 12.10. Becton Dickinson and Company

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us